Our Story

Following decades of large-scale trials probing the utility of cell-based regenerative therapies, RION’s co-founders Dr. Andre Terzic and Dr. Atta Behfar discovered that the driving force behind tissue repair was exosome signaling.

This pivotal discovery launched RION’s vision to redefine regenerative medicine. By leveraging their exosome research, Drs. Behfar and Terzic envisioned a new paradigm in healing by harnessing these extracellular vesicles, they knew the clinical landscape could be transformed if the key exosome, capable to drive tissue regeneration in the body, could be identified and isolated. Their aspirations materialized with the first iteration of the Purified Exosome Product™ (PEP™ ) in Dr. Behfar’s Mayo Clinic laboratory, whose regenerative performance eclipsed any other technology the team had ever studied.

Following decades of large-scale trials probing the utility of cell-based regenerative therapies, RION’s co-founders Dr. Andre Terzic and Dr. Atta Behfar were among the earliest scientists of their generation to observe that the driving force behind tissue repair was exosome signaling.

This pivotal discovery launched RION’s vision to redefine regenerative medicine. By leveraging their exosome research, Drs. Behfar and Terzic envisioned a new paradigm in healing by harnessing these extracellular vesicles, they knew the clinical landscape could be transformed by the utility of a low-maintenance regenerative therapeutic, one fulfilling a long-delayed promise of cell-based therapies. Their commitment to this vision was materialized in the creation of the first iteration of the Purified Exosome Product™ (PEP™) in Dr. Behfar’s Mayo Clinic laboratory, targeting long standing medical challenges with this novel biological tool.